Mercy BioAnalytics Overview

  • Year Founded
  • 2018

Year Founded

  • Status
  • Private

  • Employees
  • 47

Employees

  • Latest Deal Type
  • Series B

  • Latest Deal Amount
  • $59M

  • Investors
  • 24

Mercy BioAnalytics General Information

Description

Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detection of cancer. The company's platform interrogates tumor-derived extracellular vesicles, which are abundant in blood and carry information about their cell of origin, enabling patients to detect various types of cancer at the earliest stages.

Contact Information

Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Corporate Office
  • 880 Winter Street
  • Suite 2003
  • Waltham, MA 02451
  • United States
+1 (480)
Primary Industry
Decision/Risk Analysis
Other Industries
Diagnostic Equipment
Laboratory Services (Healthcare)
Corporate Office
  • 880 Winter Street
  • Suite 2003
  • Waltham, MA 02451
  • United States
+1 (480)

Mercy BioAnalytics Timeline

2023202420252026
Financing RoundCaptured Employee CountEstimated Employee Growth

Want detailed data on 11M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Mercy BioAnalytics Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
5. Later Stage VC (Series B) 28-Aug-2025 $59M Completed Generating Revenue
4. Later Stage VC (Series A) 08-Mar-2023 Completed Generating Revenue
3. Seed Round 29-Jan-2021 Completed Generating Revenue
2. Accelerator/Incubator Completed Generating Revenue
1. Accelerator/Incubator Completed Generating Revenue
To view Mercy BioAnalytics’s complete valuation and funding history, request access »

Mercy BioAnalytics Cap Table

Stock # of Shares
Authorized
Par Value Dividend Rate (%) Original
Issue Price
Liquidation Liquidation
Pref. Multiple
Conversion Price % Owned
Series A
Seed
To view Mercy BioAnalytics’s complete cap table history, request access »

VC Exit Predictor

See how our proprietary methodology utilizes historical data sets to synthesize the likelihood of an acquisition, IPO, or no exit event. Get a detailed look at the calculations behind our predictions.

Opportunity Score

Calculated using Exit Type probabilities, the company’s stage, and PitchBook’s historical returns data.

Exit Type

Evaluates the likelihood of a successful exit for investors, and the most likely exit type.

Mercy BioAnalytics Comparisons

Description
Primary
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last
Financing
Details
Developer of a novel liquid biopsy assay platform designed to relieve suffering and save lives through the early detecti
Decision/Risk Analysis
Waltham, MA
47 As of 2025

Brisbane, CA
 
Add Comparison

PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.

Request a free trial

Mercy BioAnalytics Competitors (1)

One of Mercy BioAnalytics’s competitors is Freenome, a Formerly VC-backed company based in Brisbane, CA.

Company Name Financing Status Location Employees Total Raised Last Financing Date/Type Last Financing Amount
Freenome Formerly VC-backed Brisbane, CA
You’re viewing 1 of 1 competitors. Get the full list »

Mercy BioAnalytics Patents

Mercy BioAnalytics Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
WO-2026226814-A1 Methods of biomarker detection on particles Pending 24-Apr-2025
US-20260338785-A1 Multiplex method for multiple biomarker detection on particles Pending 24-Apr-2025
WO-2026226813-A1 Multiplex method for multiple biomarker detection on particles Pending 24-Apr-2025
WO-2026226815-A1 Multiplex method for multiple biomarker detection on particles Pending 24-Apr-2025
EP-4837131-A1 Pooling samples for screening diagnostics Pending 03-Jan-2025
To view Mercy BioAnalytics’s complete patent history, request access »

Mercy BioAnalytics Signals

Growth Rate

Weekly
Growth
Weekly Growth

Size Multiple

Median
Size Multiple

Key Data Points

Similarweb Unique Visitors

Majestic Referring Domains

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Mercy BioAnalytics Investors (24)

Investor Name Investor Type Holding Investor Since Participating Rounds
Hologic PE-Backed Company Minority
Mindshift Capital Venture Capital Minority
Perceptive Advisors Venture Capital Minority
Portfolia Venture Capital Minority
Xontogeny Accelerator/Incubator Minority
You’re viewing 5 of 24 investors. Get the full list »

Mercy BioAnalytics FAQs

  • When was Mercy BioAnalytics founded?

    Mercy BioAnalytics was founded in 2018.

  • Where is Mercy BioAnalytics headquartered?

    Mercy BioAnalytics is headquartered in Waltham, MA.

  • What is the size of Mercy BioAnalytics?

    Mercy BioAnalytics has 47 total employees.

  • What industry is Mercy BioAnalytics in?

    Mercy BioAnalytics’s primary industry is Decision/Risk Analysis.

  • Is Mercy BioAnalytics a private or public company?

    Mercy BioAnalytics is a Private company.

  • What is Mercy BioAnalytics’s current revenue?

    The current revenue for Mercy BioAnalytics is .

  • How much funding has Mercy BioAnalytics raised over time?

    Mercy BioAnalytics has raised $127M.

  • Who are Mercy BioAnalytics’s investors?

    Hologic, Mindshift Capital, Perceptive Advisors, Portfolia, and Xontogeny are 5 of 24 investors who have invested in Mercy BioAnalytics.

  • Who are Mercy BioAnalytics’s competitors?

    Freenome is a competitor of Mercy BioAnalytics.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read more
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process